Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy

Shuchi Desai, Sadia Khanani, Mujeeb Shad, E. Sherwood Brown

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

BACKGROUND: Excessive corticosteroid exposure is associated with atrophic effects on the human hippocampus and amygdala. These effects seem to be, at least in part, mediated through corticosteroid-induced release of glutamate. We previously reported that lamotrigine, a glutamate release inhibitor, significantly improved declarative memory but did not change hippocampal volume, as compared with placebo, in corticosteroid-treated patients. To our knowledge, no data are available on preventing or reversing the impact of corticosteroids on the amygdala. METHODS: We examined the effects of 24 weeks of randomized placebo-controlled lamotrigine therapy on amygdala volume and mood in 28 corticosteroid-treated patients (n ≤ 12, placebo; n ≤ 16, lamotrigine). Amygdala volumes were measured from tracings of the magnetic resonance images from weeks 0 and 24. Mood was assessed every 2 weeks with the Hamilton Depression Rating Scale and the Young Mania Rating Scale. RESULTS: An analysis of covariance revealed that patients on lamotrigine had significantly larger left amygdala volume at week 24 than patients on placebo after controlling for baseline volume. Neither exit nor week 24 analysis of covariance of Hamilton Depression Rating Scale and Young Mania Rating Scale revealed a significant difference between lamotrigine and placebo groups. CONCLUSIONS: Results suggest that lamotrigine attenuated the effects of corticosteroids on the left amygdala. Larger trials are warranted to confirm these findings.

Original languageEnglish (US)
Pages (from-to)284-287
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume29
Issue number3
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Amygdala
Atrophy
Adrenal Cortex Hormones
Placebos
Bipolar Disorder
Glutamic Acid
Therapeutics
Depression
lamotrigine
Hippocampus
Magnetic Resonance Spectroscopy

Keywords

  • Amygdala
  • Atrophy
  • Corticosteroid
  • Lamotrigine
  • Volume

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy. / Desai, Shuchi; Khanani, Sadia; Shad, Mujeeb; Brown, E. Sherwood.

In: Journal of Clinical Psychopharmacology, Vol. 29, No. 3, 06.2009, p. 284-287.

Research output: Contribution to journalArticle

Desai, Shuchi ; Khanani, Sadia ; Shad, Mujeeb ; Brown, E. Sherwood. / Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy. In: Journal of Clinical Psychopharmacology. 2009 ; Vol. 29, No. 3. pp. 284-287.
@article{e712357b68f14cec8eab852d187a9053,
title = "Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy",
abstract = "BACKGROUND: Excessive corticosteroid exposure is associated with atrophic effects on the human hippocampus and amygdala. These effects seem to be, at least in part, mediated through corticosteroid-induced release of glutamate. We previously reported that lamotrigine, a glutamate release inhibitor, significantly improved declarative memory but did not change hippocampal volume, as compared with placebo, in corticosteroid-treated patients. To our knowledge, no data are available on preventing or reversing the impact of corticosteroids on the amygdala. METHODS: We examined the effects of 24 weeks of randomized placebo-controlled lamotrigine therapy on amygdala volume and mood in 28 corticosteroid-treated patients (n ≤ 12, placebo; n ≤ 16, lamotrigine). Amygdala volumes were measured from tracings of the magnetic resonance images from weeks 0 and 24. Mood was assessed every 2 weeks with the Hamilton Depression Rating Scale and the Young Mania Rating Scale. RESULTS: An analysis of covariance revealed that patients on lamotrigine had significantly larger left amygdala volume at week 24 than patients on placebo after controlling for baseline volume. Neither exit nor week 24 analysis of covariance of Hamilton Depression Rating Scale and Young Mania Rating Scale revealed a significant difference between lamotrigine and placebo groups. CONCLUSIONS: Results suggest that lamotrigine attenuated the effects of corticosteroids on the left amygdala. Larger trials are warranted to confirm these findings.",
keywords = "Amygdala, Atrophy, Corticosteroid, Lamotrigine, Volume",
author = "Shuchi Desai and Sadia Khanani and Mujeeb Shad and Brown, {E. Sherwood}",
year = "2009",
month = "6",
doi = "10.1097/JCP.0b013e3181a3e2a7",
language = "English (US)",
volume = "29",
pages = "284--287",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy

AU - Desai, Shuchi

AU - Khanani, Sadia

AU - Shad, Mujeeb

AU - Brown, E. Sherwood

PY - 2009/6

Y1 - 2009/6

N2 - BACKGROUND: Excessive corticosteroid exposure is associated with atrophic effects on the human hippocampus and amygdala. These effects seem to be, at least in part, mediated through corticosteroid-induced release of glutamate. We previously reported that lamotrigine, a glutamate release inhibitor, significantly improved declarative memory but did not change hippocampal volume, as compared with placebo, in corticosteroid-treated patients. To our knowledge, no data are available on preventing or reversing the impact of corticosteroids on the amygdala. METHODS: We examined the effects of 24 weeks of randomized placebo-controlled lamotrigine therapy on amygdala volume and mood in 28 corticosteroid-treated patients (n ≤ 12, placebo; n ≤ 16, lamotrigine). Amygdala volumes were measured from tracings of the magnetic resonance images from weeks 0 and 24. Mood was assessed every 2 weeks with the Hamilton Depression Rating Scale and the Young Mania Rating Scale. RESULTS: An analysis of covariance revealed that patients on lamotrigine had significantly larger left amygdala volume at week 24 than patients on placebo after controlling for baseline volume. Neither exit nor week 24 analysis of covariance of Hamilton Depression Rating Scale and Young Mania Rating Scale revealed a significant difference between lamotrigine and placebo groups. CONCLUSIONS: Results suggest that lamotrigine attenuated the effects of corticosteroids on the left amygdala. Larger trials are warranted to confirm these findings.

AB - BACKGROUND: Excessive corticosteroid exposure is associated with atrophic effects on the human hippocampus and amygdala. These effects seem to be, at least in part, mediated through corticosteroid-induced release of glutamate. We previously reported that lamotrigine, a glutamate release inhibitor, significantly improved declarative memory but did not change hippocampal volume, as compared with placebo, in corticosteroid-treated patients. To our knowledge, no data are available on preventing or reversing the impact of corticosteroids on the amygdala. METHODS: We examined the effects of 24 weeks of randomized placebo-controlled lamotrigine therapy on amygdala volume and mood in 28 corticosteroid-treated patients (n ≤ 12, placebo; n ≤ 16, lamotrigine). Amygdala volumes were measured from tracings of the magnetic resonance images from weeks 0 and 24. Mood was assessed every 2 weeks with the Hamilton Depression Rating Scale and the Young Mania Rating Scale. RESULTS: An analysis of covariance revealed that patients on lamotrigine had significantly larger left amygdala volume at week 24 than patients on placebo after controlling for baseline volume. Neither exit nor week 24 analysis of covariance of Hamilton Depression Rating Scale and Young Mania Rating Scale revealed a significant difference between lamotrigine and placebo groups. CONCLUSIONS: Results suggest that lamotrigine attenuated the effects of corticosteroids on the left amygdala. Larger trials are warranted to confirm these findings.

KW - Amygdala

KW - Atrophy

KW - Corticosteroid

KW - Lamotrigine

KW - Volume

UR - http://www.scopus.com/inward/record.url?scp=67649289849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649289849&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3181a3e2a7

DO - 10.1097/JCP.0b013e3181a3e2a7

M3 - Article

VL - 29

SP - 284

EP - 287

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 3

ER -